業績紹介

Achivement

2012年業績

• Murakami E, Aikata H, Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Takahashi S, Kimura T, Kenjo M, Nagata Y, Ishikawa M, Kakizawa H, Awai K and Chayama K.

  Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava.

  Hepatol Res. 2012; 42: 442-453.

• Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E and Kumada H.

  Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.

  Hepatology. 2012; 55: 742-748.

• Ohishi W and Chayama K.

  Treatment of chronic hepatitis B with nucleos(t)ide analogues.

  Hepatol Res. 2012; 42: 219-225.

• Yanagimoto S, Yotsuyanagi H, Kikuchi Y, Tsukada K, Kato M, Takamatsu J, Hige S, Chayama K, Moriya K and Koike K.

  Chronic hepatitis B in patients coinfected with human immunodeficiency virus in Japan: a retrospective multicenter analysis.

  J Infect Chemother. 2012; 18: 883-890.

• Kuwabara T, Hiyama T, Oka S, Urabe Y, Tanaka S, Yoshihara M, Arihiro K, Shimamoto F and Chayama K.

  Clinical features of pharyngeal intraepithelial neoplasias and outcomes of treatment by endoscopic submucosal dissection.

  Gastrointest Endosc. 2012; 76: 1095-1103.

• Miyaki D, Aikata H, Honda Y, Naeshiro N, Nakahara T, Tanaka M, Nagaoki Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Takahashi S, Ishikawa M, Kakizawa H, Awai K and Chayama K.

  Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification.

  J Gastroenterol Hepatol. 2012; 27: 1850-1857.

• Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T and Chayama K.

  Serum levels of pigment epithelium-derived factor (PEDF) are independently associated with procollagen III N-terminal peptide levels in patients with nonalcoholic fatty liver disease.

  Clin Biochem. 2012; 45: 1554-1557.

• Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arihiro K, Aikata H, Takahashi S and Chayama K.

  Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study.

  Hepatol Res. 2012; 42: 1065-1072.

• Tatsugami M, Ito M, Tanaka S, Yoshihara M, Matsui H, Haruma K and Chayama K.

  Bile Acid promotes intestinal metaplasia and gastric carcinogenesis.

  Cancer Epidemiol Biomarkers Prev. 2012; 21: 2101-2107.

• Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T and Chayama K.

  Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance.

  Dig Liver Dis. 2012; 44: 935-939.

• Okusaka T, Kasugai H, Ishii H, Kudo M, Sata M, Tanaka K, Shioyama Y, Chayama K, Kumada H, Yoshikawa M, Seki T, Saito H, Hayashi N, Shiratori K, Okita K, Sakaida I, Honda M, Kusumoto Y, Tsutsumi T and Sakata K.

  A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma.

  Invest New Drugs. 2012; 30: 2015-2025.

• Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H and Chayama K.

  Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.

  J Gastroenterol Hepatol. 2012; 27: 1467-1472.

• Chayama K, Hayes CN and Imamura M.

  Impact of interleukin-28B genotype on in vitro and in vivo systems of hepatitis C virus replication.

  Hepatol Res. 2012; 42: 841-853.

• Kawaoka T, Hiraga N, Takahashi S, Takaki S, Tsuge M, Nagaoki Y, Hashimoto Y, Katamura Y, Miki D, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Ochi H, Tashiro H, Ohdan H and Chayama K.

  Achievement of sustained viral response after switching treatment from pegylated interferon alpha-2b to alpha-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.

  Intervirology. 2012; 55: 306-310.

• Okanobu H, Ito M, Tanaka S, Onogawa S, Akagi M, Oh EH, Nagata S, Okamoto S, Kuwai T, Cho S, Matsumoto Y, Kitamura S, Hidaka T and Chayama K.

  Evaluation of Individual Risk in Nonvariceal Gastrointestinal Bleeding Patients with NSAID Administration: A Multicenter Study in Japan.

  Digestion. 2012; 86: 187-193.

• Okazaki A, Hiraga N, Imamura M, Hayes CN, Tsuge M, Takahashi S, Aikata H, Abe H, Miki D, Ochi H, Tateno C, Yoshizato K, Ohdan H and Chayama K.

  Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse.

  Hepatology. 2012; 56: 555-566.

• Nakadoi K, Tanaka S, Hayashi N, Ozawa S, Terasaki M, Takata S, Kanao H, Oka S and Chayama K.

  Clinical outcomes of endoscopic submucosal dissection for rectal tumor close to the dentate line.

  Gastrointest Endosc. 2012; 76: 444-450.

• Kohno T, Tsuge M, Hayes CN, Hatakeyama T, Ohnishi M, Abe H, Miki D, Hiraga N, Imamura M, Takahashi S, Ochi H, Tanaka S and Chayama K.

  Identification of novel HCV deletion mutants in chronic hepatitis C patients.

  Antivir Ther. 2012; 17: 1551-1561.

• Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y and Kumada H.

  Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.

  Intervirology. 2012; 55: 231-241.

• Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, Kimura Y, Miki D, Hiraga N, Imamura M, Takahashi S, Ochi H, Hayes CN, Tanaka S, Arihiro K and Chayama K.

  IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.

  J Gastroenterol. 2012; 47: 834-844.

• Matsuo J, Mizui M, Okita H, Katayama K, Aimitsu S, Sakata T, Obayashi M, Nakanishi T, Chayama K, Miyakawa Y, Yoshizawa H, Tanaka J and for the Hiroshima Hepatitis Study G.

  Follow up of the 987 blood donors found with hepatitis C virus infection over 9-18 years.

  Hepatol Res. 2012; 42: 637-647.

• Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, Chayama K, Kosuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T and Nakagawa H.

  Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.

  Nat Genet. 2012; 44: 760-764.

• Hayes CN, Imamura M, Aikata H and Chayama K.

  Genetics of IL28B and HCV--response to infection and treatment.

  Nat Rev Gastroenterol Hepatol. 2012; 9: 406-417.

• Kanbara A, Miura Y, Hyogo H, Chayama K and Seyama I.

  Effect of urine pH changed by dietary intervention on uric acid clearance mechanism of pH-dependent excretion of urinary uric acid.

  Nutr J. 2012; 11: 39.

• Shishido T, Oka S, Tanaka S, Aoyama T, Watari I, Imagawa H, Yoshida S and Chayama K.

  Diagnostic yield of capsule endoscopy vs. double-balloon endoscopy for patients who have undergone total enteroscopy with obscure gastrointestinal bleeding.

  Hepatogastroenterology. 2012; 59: 955-959.

• Nakadoi K, Tanaka S, Kanao H, Terasaki M, Takata S, Oka S, Yoshida S, Arihiro K and Chayama K.

  Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection.

  J Gastroenterol Hepatol. 2012; 27: 1057-1062.

• Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T and Chayama K.

  Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-alpha-lowering property.

  Dig Liver Dis. 2012; 44: 492-496.

• Oshita A, Tashiro H, Amano H, Kobayashi T, Onoe T, Ide K, Takaki S, Takahashi S, Arihiro K, Chayama K and Ohdan H.

  Safety and feasibility of diet-treated donors with steatotic livers at the initial consultation for living-donor liver transplantation.

  Transplantation. 2012; 93: 1024-1030.

• Miki D, Ochi H, Hayes CN, Aikata H and Chayama K.

  Hepatocellular carcinoma: towards personalized medicine.

  Cancer Sci. 2012; 103: 846-850.

• Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T and Jsg N.

  Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study.

  J Gastroenterol. 2012; 47: 586-595.

• Hotta K, Kitamoto A, Kitamoto T, Mizusawa S, Teranishi H, So R, Matsuo T, Nakata Y, Hyogo H, Ochi H, Nakamura T, Kamohara S, Miyatake N, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Yoneda M, Nakajima A, Funahashi T, Miyazaki S, Tokunaga K, Masuzaki H, Ueno T, Chayama K, Hamaguchi K, Yamada K, Hanafusa T, Oikawa S, Yoshimatsu H, Sakata T, Tanaka K, Matsuzawa Y, Nakao K and Sekine A.

  Association between type 2 diabetes genetic susceptibility loci and visceral and subcutaneous fat area as determined by computed tomography.

  J Hum Genet. 2012; 57: 305-310.

• Kobayashi M, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Miyakawa Y and Kumada H.

  Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.

  J Gastroenterol. 2012; 47: 596-605.

• Iiboshi T, Hanada K, Fukuda T, Yonehara S, Sasaki T and Chayama K.

  Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer: establishing a new method for the early detection of pancreatic carcinoma in situ.

  Pancreas. 2012; 41: 523-529.

• Hashimoto M, Kobayashi T, Tashiro H, Amano H, Oshita A, Tanimoto Y, Kuroda S, Tazawa H, Aikata H, Chayama K, Fujii M, Arihiro K and Ohdan H.

  A huge metastatic liver tumor from leiomyosarcoma of the inferior vena cava: report of a case.

  Surg Today. 2012; 42: 505-508.

• Oka S, Tanaka S, Takata S, Kanao H and Chayama K.

  Usefulness and safety of SB knife Jr in endoscopic submucosal dissection for colorectal tumors.

  Dig Endosc. 2012; 24: S90-95.

• Tanaka S, Terasaki M, Kanao H, Oka S and Chayama K.

  Current status and future perspectives of endoscopic submucosal dissection for colorectal tumors.

  Dig Endosc. 2012; 24: S73-79.

• Terasaki M, Tanaka S, Oka S, Nakadoi K, Takata S, Kanao H, Yoshida S and Chayama K.

  Clinical outcomes of endoscopic submucosal dissection and endoscopic mucosal resection for laterally spreading tumors larger than 20 mm.

  J Gastroenterol Hepatol. 2012; 27: 734-740.

• Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S and Chayama K.

  Recent trend of clinical features in patients with hepatocellular carcinoma.

  Hepatol Res. 2012; 42: 368-375.

• Onji K, Yoshida S, Tanaka S, Takemura Y, Oka S, Yoshihara M, Yamada H, Okajima M and Chayama K.

  Microvascular structure and perfusion imaging of colon cancer by means of contrast-enhanced ultrasonography.

  Abdom Imaging. 2012; 37: 297-303.

• Urabe Y, Tanikawa C, Takahashi A, Okada Y, Morizono T, Tsunoda T, Kamatani N, Kohri K, Chayama K, Kubo M, Nakamura Y and Matsuda K.

  A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible Loci at 5q35.3, 7p14.3, and 13q14.1.

  PLoS Genet. 2012; 8: e1002541.

• Ishikawa M, Kakizawa H, Hieda M, Toyota N, Katamura Y, Aikata H, Chayama K and Awai K.

  Long-term outcomes of hepatic arterial port implantation using a coaxial microcatheter system in 176 patients with hepatocellular carcinoma.

  Hiroshima J Med Sci. 2012; 61: 7-13.

• Shishido T, Oka S, Tanaka S, Imagawa H, Takemura Y, Yoshida S and Chayama K.

  Outcome of patients who have undergone total enteroscopy for obscure gastrointestinal bleeding.

  World J Gastroenterol. 2012; 18: 666-672.

• Kuwabara T, Chayama K, Tanaka S, Oka S, Hiyama T and Yoshihara M.

  Compliance with standard precautions among gastrointestinal endoscopists and endoscopy nurses in Japan.

  Am J Infect Control. 2012; 40: 80.

• Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Takahashi S, Itamoto T, Chayama K and Ohdan H.

  Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection.

  Ann Surg Oncol. 2012; 19: 418-425.

• Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K and Kumada H.

  Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.

  J Viral Hepat. 2012; 19: e134-142.

• Miki D, Ohishi W, Ochi H, Hayes CN, Abe H, Tsuge M, Imamura M, Kamatani N, Nakamura Y and Chayama K.

  Serum PAI-1 is a novel predictor for response to pegylated interferon-alpha-2b plus ribavirin therapy in chronic hepatitis C virus infection.

  J Viral Hepat. 2012; 19: e126-133.

• Sainz B, Jr., Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA and Uprichard SL.

  Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.

  Nat Med. 2012; 18: 281-285.

• Matsumoto A, Tanaka E, Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, Hige S, Yatsuhashi H, Nagaoka S, Chayama K, Tsuge M, Yokosuka O, Imazeki F, Nishiguchi S, Saito M, Fujiwara K, Torii N, Hiramatsu N, Karino Y and Kumada H.

  Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.

  Hepatol Res. 2012; 42: 139-149.

• Ochi H, Hayes CN, Abe H, Hayashida Y, Uchiyama T, Kamatani N, Nakamura Y and Chayama K.

  Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C.

  J Infect Dis. 2012; 205: 204-210.

• Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Fujita K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T and Japan Study Group of Nonalcoholic Fatty Liver D.

  Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population.

  BMC Gastroenterol. 2012; 12: 2.

• Takemura Y, Yoshida S, Tanaka S, Kawase R, Onji K, Oka S, Tamaki T, Raytchev B, Kaneda K, Yoshihara M and Chayama K.

  Computer-aided system for predicting the histology of colorectal tumors by using narrow-band imaging magnifying colonoscopy (with video).

  Gastrointest Endosc. 2012; 75: 179-185.

• Hotta K, Kitamoto A, Kitamoto T, Mizusawa S, Teranishi H, Matsuo T, Nakata Y, Hyogo H, Ochi H, Nakamura T, Kamohara S, Miyatake N, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Yoneda M, Nakajima A, Funahashi T, Miyazaki S, Tokunaga K, Masuzaki H, Ueno T, Chayama K, Hamaguchi K, Yamada K, Hanafusa T, Oikawa S, Yoshimatsu H, Sakata T, Tanaka K, Matsuzawa Y, Nakao K and Sekine A.

  Genetic variations in the CYP17A1 and NT5C2 genes are associated with a reduction in visceral and subcutaneous fat areas in Japanese women.

  J Hum Genet. 2012; 57: 46-51.

• Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H and Hayashi N.

  Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.

  J Hepatol. 2012; 56: 78-84.

• Sanomura Y, Oka S, Tanaka S, Noda I, Higashiyama M, Imagawa H, Shishido T, Yoshida S, Hiyama T, Arihiro K and Chayama K.

  Clinical validity of endoscopic submucosal dissection for submucosal invasive gastric cancer: a single-center study.

  Gastric Cancer. 2012; 15: 97-105.

• Hiyama T, Yoshihara M, Tanaka S and Chayama K.

  Change in malpractice claims in Japanese gastroenterological practice.

  Am J Gastroenterol. 2012; 107: 143-144.

• Yoshioka K, Ueno Y, Tanaka S, Nagai K, Onitake T, Hanaoka R, Watanabe H and Chayama K.

  Role of natural killer T cells in the mouse colitis-associated colon cancer model.

  Scand J Immunol. 2012; 75: 16-26.

• Matsuo T, Ito M, Tatsugami M, Boda T, Takata S, Tanaka S and Chayama K.

  Gastric cancer development after Helicobacter pylori eradication therapy: a new form of gastric neoplasia.

  Digestion. 2012; 85: 61-67.

• Hayes CN, Akamatsu S, Tsuge M, Miki D, Akiyama R, Abe H, Ochi H, Hiraga N, Imamura M, Takahashi S, Aikata H, Kawaoka T, Kawakami Y, Ohishi W and Chayama K.

  Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle.

  PLoS One. 2012; 7: e47490.

• Yamasaki W, Kakizawa H, Ishikawa M, Date S, Tatsugami F, Terada H, Masaki K, Kawaoka T, Tsuge M, Aikata H, Chayama K and Awai K.

  Migration to the pulmonary artery of nine metallic coils placed in the internal iliac vein for treatment of giant rectal varices.

  Acta Radiol Short Rep. 2012; 1.

• Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y and Kumada H.

  Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment.

  Intervirology. 2012; 55: 417-425.

• Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, Hiramatsu A, Waki K, Takahashi S and Chayama K.

  Evaluation of the mRECIST and alpha-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.

  Oncology. 2012; 83: 192-200.

• E. Ohara YK, M. Onoyama, M. Ohnishi, K. Shinagawa, S. Oka, S. Yoshida, S. Tanaka, N. Sakamoto, W. Yasui, F. Shimamoto, K. Chayama.

  Regression of rectal MALT lymphoma after antibiotic treatment in a patient negative for Helicobacter pylori.

  Clinical Journal of Gastroenterology. 2012; 5: 59-63.